Overview
Properties
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 6 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Synthetic
Applications
Our Abpromise guarantee covers the use of ab120382 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| Functional Studies | FuncS: Use at an assay dependent concentration. |
Z-VAD-FMK images
-
Functional Studies - Z-VAD-FMK (ab120382)HeLa cells were incubated at 37°C for 1h with vehicle control (0 µM) and different concentrations of Z-VAD-FMK (ab120382). After this incubation 10µM of camptothecin (ab120115) was added to all samples and the cells were incubated for further 24h. Increased expression of full length PARP (ab37722) in camptothecin induced apoptotic HeLA cells correlates with an increase in Z-VAD-FMK concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab37722 at 1 µg /ml and ab8227 at 1 µg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
References for Z-VAD-FMK (ab120382)
This product has been referenced in:
- Vandenabeele P et al. Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006:pe44 (2006). Read more (PubMed: 17062895) »
- Ekert PG et al. Caspase inhibitors. Cell Death Differ 6:1081-6 (1999). Read more (PubMed: 10578177) »
- Garcia-Calvo M et al. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 273:32608-13 (1998). Read more (PubMed: 9829999) »
